NCT04214886View on ClinicalTrials.gov

CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 31, 2019

Primary Completion Date

August 11, 2022

Study Completion Date

December 31, 2034

Conditions
B-Cell Acute Lymphoblastic Leukemia, AdultB-cell Lymphoma RefractoryB-cell Lymphoma Recurrent
Interventions
DRUG

Fludarabine

Fludarabine is an anti-cancer drug acting as an antimetabolite that is used to treat leukemia and lymphoma cancers.

DRUG

Cyclophosphamide

Cyclophosphamide is is an anti-cancer drug acting as an alkylating agent that is used to treat leukemia and lymphoma cancers.

BIOLOGICAL

CD19-CD34 CAR transduced T cells

CD19-CD34 CAR transduced T cells are the subject's own immune cells that target B cell markers on cancer cells.

Trial Locations (1)

60153

Loyola University, Maywood

Sponsors
All Listed Sponsors
collaborator

Leukemia Research Foundation

UNKNOWN

lead

Loyola University

OTHER